Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
M&A
Advertisement
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Pfizer and Innovent Forge $10.5B Global Oncology Alliance
NEW YORK, SAN FRANCISCO, and SUZHOU, China, May 28, 2026 Pfizer Inc. and Innovent Biologics have announced a landmark...
Lilly Acquires Curevo, LimmaTech and Vaccine Company
INDIANAPOLIS, United States, May 26, 2026 Eli Lilly and Company has announced three major biotechnology acquisitions aimed at significantly...
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
Advertisements
Boehringer Expands Immunology Pipeline With Immunitas Deal
INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...
LEO Pharma Acquires Replay to Boost Gene Therapy
Ballerup, Denmark | April 30, 2026 LEO Pharma has announced a definitive agreement to acquire Replay, significantly expanding its...
Fagron Expands U.S. Compounding Platform With UCP Deal
Nazareth, Belgium / Rotterdam, Netherlands | January 12, 2026 — Fagron has completed the acquisition of University Compounding Pharmacy...
Advertisement
